Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024

Antunes, Liliana ✉; Mazagatos, Clara; Martinez-Baz, Ivan; Naesens, Reinout; Borg, Maria-Louise; Petrovic, Goranka; Fatukasi, Terra; Jancoriene, Ligita; Machado, Ausenda; Oroszi, Beatrix [Oroszi, Beatrix (népegészségügy, o...), szerző] Epidemiológiai és Surveillance Központ (SE / KSZE); Husa, Petr; Lazar, Mihaela; Duerrwald, Ralf; Howard, Jennifer; Melo, Aryse; Perez-Gimeno, Gloria; Castilla, Jesus; Bernaert, Eva; Dziugyte, Ausra; Makaric, Zvjezdana Lovric; Fitzgerald, Margaret; Mickiene, Aukse; Gomez, Veronica; Turi, Gergo [Túri, Gergő (népegészségügy), szerző] Epidemiológiai és Surveillance Központ (SE / KSZE); Souckova, Lenka; Marin, Alexandru; Tolksdorf, Kristin; Nicolay, Nathalie; Rose, Angela M. C.; European Hosp Vaccine Effectiveness Grp [Kollaborációs szervezet]

Angol nyelvű Sokszerzős vagy csoportos szerzőségű szakcikk (Folyóiratcikk) Tudományos
Megjelent: INFLUENZA AND OTHER RESPIRATORY VIRUSES 1750-2640 1750-2659 18 (8) Paper: e13360 , 7 p. 2024
  • SJR Scopus - Infectious Diseases: D1
Azonosítók
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged >= 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (>= 65 years) up to 1 month post vaccination.
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2026-09-13 06:53